tbuckley/cabot-search huggingface dataset:
Antibiotic susceptibility and genotypic characterization of Haemophilus influenzae strains isolated from nasopharyngeal specimens from children in day-care centers in eastern France
Authors: D. Talon, J. Leroy, M.J. Dupont, X. Bertrand, F. Mermet, M. Thouverez, J.M. Estavoyer
Journal: Clinical Microbiology and Infection (2000)
Reply to Yan Shibing and Wei Qiang's Letter to the Editor re: Morgan Rouprêt, Marko Babjuk, Eva Compérat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868–79
Authors: Morgan Rouprêt
Journal: European Urology (2015)
Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction
Authors: Y Nizet, S Van Daele, P Lewalle, JL Vaerman, M Philippe, C Vermylen, G Cornu, A Ferrant, JL Michaux, P Martiat
Journal: Blood (1993)
Prevalent low-grade dysplasia: the strongest predictor of malignant progression in Barrett's columnar-lined oesophagus
Authors: Lisa H Moyes, Karin A Oien, Alan K Foulis, Grant M Fullarton, James J Going
Journal: Gut (2015)

We read with interest the work by Duits et al 1 who find that validated low-grade dysplasia (LGD) is highly predictive of malignant progression in Barrett's oesophagus (BO).Yachimski 2 stresses the need for this important finding to be validated in other centres.Our experience of prevalent LGD as a predictor of malignant progression in BO in the West of Scotland strongly reinforces the conclusions of our colleagues in the Netherlands.Patients with BO diagnosed between 1994 and 2009 at one centre (Glasgow Royal Infirmary (GRI)) all had BO visible endoscopically, with biopsy-proven metaplastic glandular mucosa in the tubular oesophagus.Exclusions for residence outside GRI catchment area, severe comorbidities, refusal of surveillance, loss to follow-up, high-grade dysplasia (HGD) or oesophageal adenocarcinoma (OA) at diagnosis (or ascertained within 1 year of index endoscopy), or being indefinite for dysplasia (n=15) left 145 short (≤3 cm) and 577 long (>3 cm) patients with BO in surveillance.Biopsy protocol was by endoscopist's choice.Endoscopy was biennial without LGD, and 3-6 monthly after LGD ascertainment.Patients with new HGD or OA were offered endoscopic treatment or surgery.Proton pump inhibitors (PPIs) were prescribed throughout.Death and its causes were ascertained from the regional registrar.Follow-up was from entry to progression, death or 31 December 2012.Age and BO length thresholds were taken as <65, 65-74, >75 years; ≤3 cm, >3 cm.Progression-free survival was examined with the Kaplan-Meier estimator and Cox's proportional hazards regression of progression to HGD or OA with the following factors: prevalent dysplasia as originally reported, age, gender, segment length and social deprivation, using R V.3.0.2, with libraries survival and muhaz.Our 722-person cohort of 437 men (1st quartile:median:3rd quartile 53:63:72 years) and 285 women (61:69:78 years) underwent 74 989 months' follow-up (75:109:137 months).N=58 patients with prevalent dysplasia were slightly older (median 67 vs 64 years, p<0.05) and more likely to be male (40 men, 18 women, p<0.02).Of these 58, 21 (36%) progressed to HGD (9) or OA (12) at overall rates of 2.0% and 2.7% per annum, respectively ( p<0.001).Of the 664 patients without identified prevalent dysplasia, 85 progressed: 54 (8%) to LGD at 0.93% per annum.Only 10 (1.5%) developed HGD at 0.17% per annum and 21 (3.2%)OA, at 0.36% per annum.LGD was powerfully predictive of progression, with HR 10.8 (95% CI 5.9 to 18.1) for progression to 360
Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation
Authors: Justin Sperlazza, Mohamed Rahmani, Jason Beckta, Mandy Aust, Elisa Hawkins, Shou Zhen Wang, Sheng Zu Zhu, Shreya Podder, Catherine Dumur, Kellie Archer, Steven Grant, Gordon D. Ginder
Journal: Blood (2015)

Key Points CHD4 depletion sensitizes AML cells but not normal CD34+ progenitors to genotoxic agents by relaxing chromatin and impairing DSB repair. CHD4 depletion modulates expression of AML cell genes that regulate tumor formation in vivo and colony formation in vitro.
Variability of FVC and FEV1 due to technician, team, device and subject in an eight centre study: three quality control studies in SAPALDIA. Swiss Study on Air Pollution and Lung Disease in Adults
Authors: N Kunzli, U Ackermann-Liebrich, R Keller, AP Perruchoud, C Schindler
Journal: European Respiratory Journal (1995)

Lung function testing of a random population sample in the eight SAPALDIA (Swiss study on air pollution and lung diseases in adults) centres had to be performed simultaneously, within one year, by eight teams and 23 technicians. We conducted quality control studies to test for technician, team and device related systematic measurement errors. To assess technician effects, each centre conducted a study involving 12-19 subjects. Two studies with 13 participants each addressed team and device effects. In all studies, volunteers repeatedly performed spirometry with different technicians or devices. Effects due to technician, team or device were estimated (analysis of variance). Neither "technician" within any of eight teams nor "team" accounted for significant differences of forced vital capacity (FVC) or forced expiratory volume in one second (FEV1). The Device Effect Study revealed 10% lower FVC values for device No. 1 due to a technical problem occurring during the test day but not in the main SAPALDIA study. Further investigations revealed potential hardware and software sources of error which are not recognizable by trained technicians. These studies gave no evidence for systematic errors due to technician, team or device during the main SAPALDIA study. However, they revealed potential sources of error in modern devices, which function as "black boxes". Manufacturers should improve spirometry software to further enhance the technicians' attempts at accurate assessment.
Effects of a soluble guanylate cyclase stimulator, BAY 41-8543, upon right ventricular function in experimental pulmonary embolism
Authors: John Watts, Michael Gellar, Mary-Beth Fulkerson, Jeffrey Kline
Journal: European Respiratory Journal (2012)

Background : Pulmonary embolism (PE) increases pulmonary vascular resistance (PVR) and may cause right ventricular (RV) dysfunction, leading to poor clinical outcome. Our studies show BAY 41-8543 reduces PVR in experimental PE (Watts, J.A. et al., Crit Care Med 2011; 39:2700-2704), but effects upon RV function were previously unknown. Aims : The studies test if soluble guanylate cyclase stimulator (BAY 41-8543) treatment protects RV function in experimental PE. Methods : Experimental PE was induced in anesthetized, Sprague-Dawley rats by infusing 25µm polystyrene microspheres in the right jugular vein producing severe PE (2.6 million/100 gm body wt, 5 hrs) or moderate PE (2.0 million/100 gm, 18 hrs). PVR was estimated in-Vivo. Heart function was studied ex-Vivo using Langendorff technique. Results : Moderate PE produced a significant 3-fold increase in PVR, which was prevented by BAY 41-8543 (50 µg/kg, I.V.) treatment (Control 0.6 ± 0.04; PE 1.9 ± 0.2; PE + BAY 41-8543 0.7 ± 0.04 mmHg/ml/min). Moderate PE caused a significant decrease in RV peak systolic pressure (PSP, Control 39 ± 1 mmHg vs. 19 ± 3 PE), +dP/dt (1192 ± 93 mmHg/sec vs. 444 ± 64) and -dP/dt (-576 ± 60 mmHg/sec vs. 278 ± 40). BAY 41-8543 significantly improved all three indices of RV function (PSP 35 ± 3.5, +dP/dt 1128 ± 100, -dP/dt -568 ± 87). Severe PE caused significant RV dysfunction (PSP 26 ± 2, -dP/dt -369 ± 29) and BAY 41-8543 protected RV function (PSP 34 ± 2, -dP/dt -535 ± 41). Conclusions : Experimental PE increases PVR and produces RV dysfunction. Treatment of the animals with the soluble guanylate cyclase stimulator, BAY 41-8543, reduces PVR and improves RV function.
Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array
Authors: Vinod Vathipadiekal, Victoria Wang, Wei Wei, Levi Waldron, Ronny Drapkin, Michael Gillette, Steven Skates, Michael Birrer
Journal: Clinical Cancer Research (2015)

To generate a comprehensive "Secretome" of proteins potentially found in the blood and derive a virtual Affymetrix array. To validate the utility of this database for the discovery of novel serum-based biomarkers using ovarian cancer transcriptomic data.The secretome was constructed by aggregating the data from databases of known secreted proteins, transmembrane or membrane proteins, signal peptides, G-protein coupled receptors, or proteins existing in the extracellular region, and the virtual array was generated by mapping them to Affymetrix probeset identifiers. Whole-genome microarray data from ovarian cancer, normal ovarian surface epithelium, and fallopian tube epithelium were used to identify transcripts upregulated in ovarian cancer.We established the secretome from eight public databases and a virtual array consisting of 16,521 Affymetrix U133 Plus 2.0 probesets. Using ovarian cancer transcriptomic data, we identified candidate blood-based biomarkers for ovarian cancer and performed bioinformatic validation by demonstrating rediscovery of known biomarkers including CA125 and HE4. Two novel top biomarkers (FGF18 and GPR172A) were validated in serum samples from an independent patient cohort.We present the secretome, comprising the most comprehensive resource available for protein products that are potentially found in the blood. The associated virtual array can be used to translate gene-expression data into cancer biomarker discovery. A list of blood-based biomarkers for ovarian cancer detection is reported and includes CA125 and HE4. FGF18 and GPR172A were identified and validated by ELISA as being differentially expressed in the serum of ovarian cancer patients compared with controls.
Lipooligosaccharide locus class of Campylobacter jejuni: sialylation is not needed for invasive infection
Authors: P. Ellström, B. Feodoroff, M.-L. Hänninen, H. Rautelin
Journal: Clinical Microbiology and Infection (2013)

Campylobacter jejuni is a highly diverse enteropathogen that is commonly detected worldwide. It can sometimes cause bacteraemia, but the bacterial characteristics facilitating bloodstream infection are not known. A total of 73 C. jejuni isolates, consecutively collected from blood-borne infections during a 10-year period all over Finland and for which detailed clinical information of the patients were available, were included. We screened the isolates by PCR for the lipooligosaccharide (LOS) locus class and for the presence of the putative virulence genes ceuE, ciaB, fucP, and virB11. The isolates were also tested for γ-glutamyl transpeptidase production. The results were analysed with respect to the clinical characteristics of the patients, and the multilocus sequence types (MLSTs) and serum resistance of the isolates. LOS locus classes A, B, and C, which carry genes for sialylation of LOS, were detected in only 23% of the isolates. These isolates were not more resistant to human serum than those with the genes of non-sialylated LOS locus classes, but were significantly more prevalent among patients with underlying diseases (p 0.02). The fucose permease gene fucP was quite uncommon, but was associated with the isolates with the potential to sialylate LOS (p <0.0001). LOS locus classes and some of the putative virulence factors were associated with MLST clonal complexes. Although some of the bacterial characteristics studied here have been suggested to be important for the invasiveness of C. jejuni, they did not explain why the clinical isolates in the present study were able to cause bacteraemia.
Transmitted drug-resistance in human immunodeficiency virus-infected adult population in El Salvador, Central America
Authors: Á. Holguín, G. Yebra, L. Martín, A.T. de Pineda, L.E. Ruiz, A.Y. Quezada, A.I. Nieto, G. Escobar
Journal: Clinical Microbiology and Infection (2013)
The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas
Authors: Hiroshi Nishioka, Naoko Inoshita, Ozgur Mete, Sylvia L. Asa, Kyohei Hayashi, Akira Takeshita, Noriaki Fukuhara, Mitsuo Yamaguchi-Okada, Yasuhiro Takeuchi, Shozo Yamada
Journal: Endocrine Pathology (2015)
Validation of the Vitiligo Noticeability Scale: a patient-reported outcome measure of vitiligo treatment success
Authors: J.M. Batchelor, W. Tan, S. Tour, A. Yong, A.A. Montgomery, K.S. Thomas
Journal: British Journal of Dermatology (2015)

Patient‐reported outcome measures are rarely used in vitiligo trials. The Vitiligo Noticeability Scale (VNS) is a new patient‐reported outcome measure assessing how 'noticeable' vitiligo patches are after treatment. The noticeability of vitiligo after treatment is an important indicator of treatment success from the patient's perspective. To evaluate the construct validity, acceptability and interpretability of the VNS. Clinicians (n = 33) and patients with vitiligo (n = 101) examined 39 image pairs, each depicting a vitiligo lesion pre‐ and post‐treatment. Using an online questionnaire, respondents gave a global assessment of treatment success and a VNS score for treatment response. Clinicians also estimated percentage repigmentation of lesions (< 25%; 25–50%; 51–75%; > 75%). Treatment success was defined as 'yes' on global assessment, a VNS score of 4 or 5, and > 75% repigmentation. Agreement between respondents and the different scales was assessed using kappa (κ) statistics. Vitiligo Noticeability Scale scores were associated with both patient‐ and clinician‐reported global treatment success (κ = 0·54 and κ = 0·47, respectively). Percentage repigmentation showed a weaker association with patient‐ and clinician‐reported global treatment success (κ = 0·39 and κ = 0·29, respectively). VNS scores of 4 or 5 can be interpreted as representing treatment success. Images depicting post‐treatment hyperpigmentation were less likely to be rated as successful. The VNS is a valid patient‐reported measure of vitiligo treatment success. Further validation of the VNS is required, using larger sets of clinical pre‐ and post‐treatment images, affecting a wider range of anatomical sites.
Response to preoperative multimodality therapy predicts survival in patients with carcinoma of the rectum
Authors: M. S. Roh, L. Colangelo, S. Wieand, M. O'Connell, N. Petrelli, R. Smith, E. Mamounas, D. Hyams, N. Wolmark
Journal: Journal of Clinical Oncology (2004)

3505 Background:Chemoradiation is considered standard treatment for operable rectal cancer but the optimal time to deliver this therapy is unknown. NSABP R-03 trial compared preoperative neoadjuvant to postoperative adjuvant chemoradiation. Methods:Patients were randomized to preoperative therapy (1 cycle of 5-FU[FU] and leucovorin[LV], 2 cycles of FU/LV and concomitant radiation therapy[RT], surgery, 4 cycles FU/LV) or postoperative therapy (surgery, 1 cycle of FU/LV, 2 cycles of FU/LV and concomitant RTX, 4 cycles FU/LV). The endpoints were overall (OS), disease-free (DFS) and relapse-free (RFS) survival. OS, DFS, and RFS were estimated using Kaplan-Meier curves. P-values were calculated using Greenwood's variance estimator. Results:From June 1993 to June 1999, 123 patients in the preoperative and 130 patients in the postoperative group were eligible for evaluation. Among the 78 preoperative patients evaluable for response, 25.6% had a complete clinical response (CR), 48.7% had partial (PR), 23.1% stable (SD) and 2.6% progressive but operable disease (PD). In the CR group, OS was 100% as compared to 95% in the PR group and 83% in the SD group (p-value=0.02 for CR vs. other). Corresponding values were 95%, 78%, 66% (p=0.004) for DFS and 95%, 80%, 70% (p=0.01) for RFS. Conclusions:Compared with postoperative adjuvant, preoperative neoadjuvant appears to result in improved OS, DFS and RFS. Complete responders at surgery have a significant improvement in overall, disease-free and relapse-free survival. No significant financial relationships to disclose.
The Surviving Sepsis Campaign bundles and outcome: results from the International Multicentre Prevalence Study on Sepsis (the IMPreSS study)
Authors: Andrew Rhodes, Gary Phillips, Richard Beale, Maurizio Cecconi, Jean Daniel Chiche, Daniel De Backer, Jigeeshu Divatia, Bin Du, Laura Evans, Ricard Ferrer, Massimo Girardis, Despoina Koulenti, Flavia Machado, Steven Q. Simpson, Cheng Cheng Tan, Xavier Wittebole, Mitchell Levy
Journal: Intensive Care Medicine (2015)
Dermatophagoïdes Farinae 1 (Der f1) vaccine in a mice model of allergic asthma
Authors: Camille Rolland-Debord, David Lair, Tiphaine Roussey, Julie Chesne, Guillaume Mahay, Dorian Hassoun, Bruno Pitard, Antoine Magnan
Journal: European Respiratory Journal (2013)

Allergic asthma is a chronic, inflammatory, respiratory disease caused by an abnormal reactivity against allergens.

Currently, treatments are based on specific immunotherapies, but may have potential deleterious side effects. Among new modalities of immunotherapy currently in development, DNA vaccination presents a promising approach. DNA vaccination enables specific immunotherapy in association with reduced allergenicity.

The aim of this study was to investigate the immunological mechanisms involved in Dermatophagoides farinae 1 (Der f1) DNA vaccination in our murine model of allergic asthma due to house dust mites.

For this purpose, mice have been vaccinated in a prophylactic mode with intramuscular administration of a Der f1-encoding plasmid formulated with the block copolymer 704. Then, allergic asthma was induced by sensitization and intra-nasal provocations with total extract of mite.

Our data show that vaccination with Der f1 DNA does not improve respiratory function in our model of asthmatic mice.

Pulmonary and broncho-alveolar infiltrate were more important in Der f1 vaccinated mice with a specific Th1 immune response caracterized by 1) lymphocytes recruitment, 2) increased IFN γ secretion and 3) an increased IgG2a rate.

However, vaccination with Der f1 also induces a Th2 immune response, marked by an increased of IL-4, IL-5 and IL-13 cytokines.

Der f1 DNA vaccination with 704 vector induces in our asthma model, a specific humoral and cellular response unable to protect mice.

These results could be explained by the vector itself, the amount of DNA administered and the particular immunological context of our model of asthma.
Modification of Pancreatic Carcinogenesis in the Hamster Model. XI. Inhibitory Effect of Pilocarpine Hydrochloride23
Authors: Parviz M. Pour, Terence Lawson, Thorkatla Donnelly, Katherine Stepan
Journal: JNCI Journal of the National Cancer Institute (1984)

Journal Article Modification of Pancreatic Carcinogenesis in the Hamster Model. XI. Inhibitory Effect of Pilocarpine Hydrochloride Get access Parviz M. Pour, Parviz M. Pour Search for other works by this author on: Oxford Academic PubMed Google Scholar Terence Lawson, Terence Lawson Search for other works by this author on: Oxford Academic PubMed Google Scholar Thorkatla Donnelly, Thorkatla Donnelly Search for other works by this author on: Oxford Academic PubMed Google Scholar Katherine Stepan Katherine Stepan Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 72, Issue 1, January 1984, Pages 191–194, https://doi.org/10.1093/jnci/72.1.191 Published: 01 January 1984 Article history Received: 14 June 1983 Accepted: 08 September 1983 Published: 01 January 1984
Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study.
Authors: R L Saylors, C F Stewart, W C Zamboni, D A Wall, B Bell, K C Stine, T J Vietti
Journal: Journal of Clinical Oncology (1998)

To determine the maximum-tolerated dose (MTD) and dose-limiting toxicity of topotecan when combined with cyclophosphamide in pediatric patients with recurrent or refractory malignant solid tumors.A total of 33 patients received cyclophosphamide (250 mg/m2/dose) followed by topotecan in escalating doses (0.6 to 0.75 mg/m2/dose), each given as a 30-minute infusion daily for 5 days. A total of 154 fully assessable treatment courses were given to these patients.Neutropenia was the dose-limiting toxicity of the therapy at both topotecan dose levels. The addition of filgrastim allowed escalation of the topotecan dose to the 0.75-mg/m2 level with acceptable neutropenia. Other significant toxicities were anemia and thrombocytopenia. Nonhematopoietic toxicity of grades > or = 3 was not observed. Responses were reported in patients with Wilms' tumor (one complete response [CR], one partial response [PR]), neuroblastoma (one CR, one PR), rhabdomyosarcoma (one PR), and osteosarcoma (one PR). Pharmacokinetic studies indicate that cyclophosphamide administered on the schedule used in this study did not alter topotecan disposition on day 5. As with previous studies, a pharmacodynamic relation between systemic exposure and myelosuppression was noted.The combination of topotecan and cyclophosphamide shows activity in a wide variety of pediatric solid tumors and can be given with acceptable hematopoietic toxicity with the use of filgrastim support. We recommend that pediatric phase II trials use cyclophosphamide 250 mg/m2 followed by topotecan 0.75 mg/m2 daily for 5 days with filgrastim for amelioration of neutropenia.
New insights in segmental vitiligo: case report and review of theories
Authors: N. van Geel, I. Mollet, L. Brochez, M. Dutré, S. De Schepper, E. Verhaeghe, J. Lambert, R. Speeckaert
Journal: British Journal of Dermatology (2011)

Journal Article New insights in segmental vitiligo: case report and review of theories Get access N. van Geel, N. van Geel Department of Dermatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium Nanja van Geel. E‐mail: Nanja.vangeel@UGent.be Search for other works by this author on: Oxford Academic Google Scholar I. Mollet, I. Mollet Department of Dermatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium Search for other works by this author on: Oxford Academic Google Scholar L. Brochez, L. Brochez Department of Dermatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium Search for other works by this author on: Oxford Academic Google Scholar M. Dutré, M. Dutré Department of Dermatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium Search for other works by this author on: Oxford Academic Google Scholar S. De Schepper, S. De Schepper Department of Dermatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium Search for other works by this author on: Oxford Academic Google Scholar E. Verhaeghe, E. Verhaeghe Department of Dermatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium Search for other works by this author on: Oxford Academic Google Scholar J. Lambert, J. Lambert Department of Dermatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium Search for other works by this author on: Oxford Academic Google Scholar R. Speeckaert R. Speeckaert Department of Dermatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 166, Issue 2, 1 February 2012, Pages 240–246, https://doi.org/10.1111/j.1365-2133.2011.10650.x Published: 01 February 2012 Article history Accepted: 13 September 2011 Published: 01 February 2012